View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by AIR Universita degli studi di Milano Bioorganic & Medicinal Chemistry Letters 18 (2008) 4651–4654 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl Epiboxidine and novel-related analogues: A convenient synthetic approach and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes Luca Rizzi a, Clelia Dallanoce a,*, Carlo Matera a, Pietro Magrone a, Luca Pucci b, Cecilia Gotti b, Francesco Clementi b, Marco De Amici a a Istituto di Chimica Farmaceutica e Tossicologica ‘‘Pietro Pratesi”, Università degli Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy b CNR, Istituto di Neuroscienze, Farmacologia Cellulare e Molecolare e Dipartimento Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy article info abstract Article history: Racemic exo-epiboxidine 3, endo-epiboxidine 6, and the two unsaturated epiboxidine-related derivatives Received 18 June 2008 7 and 8 were efficiently prepared taking advantage of a palladium-catalyzed Stille coupling as the key Revised 3 July 2008 step in the reaction sequence. The target compounds were assayed for their binding affinity at neuronal Accepted 4 July 2008 a4b2 and a7 nicotinic acetylcholine receptors. Epiboxidine 3 behaved as a high affinity a4b2 ligand Available online 10 July 2008 (Ki = 0.4 nM) and, interestingly, evidenced a relevant affinity also for the a7 subtype (Ki = 6 nM). Deriva- tive 7, the closest analogue of 3 in this group, bound with lower affinity at both receptor subtypes Keywords: (K = 50 nM for a4b2 and K = 1.6 lM for a7) evidenced a gain in the a4b2 versus a7 selectivity when Neuronal nicotinic acetylcholine receptors i i compared with the model compound. Epiboxidine Nicotinic ligands Ó 2008 Elsevier Ltd. All rights reserved. Binding affinity Neuronal nicotinic acetylcholine receptors (nAChRs) make up a (À)-epibatidine 2 (Fig. 1), a highly toxic alkaloid identified in the family of pentameric ligand-gated ion channels, which are formed skin of the Ecuadorian frog Epipedobates tricolor,10 has inspired a by combinations of alpha and beta subunits1,2 or exist as homo- huge amount of research aimed at designing subtype selective nic- pentamers, in the cases of a7, a8, and a9 receptors, which are otinic agonists.1,2,9,11,12 Although the pharmacological effects of inhibited by a-bungarotoxin.3 To date, nine a (a2–a10) and three (À)-2 are mediated by a variety of nAChRs,13 which preclude any b (b2–b4) isoforms have been characterized, though only a rela- therapeutic potential for epibatidine, the analgesic potency, tively small subset of combinations generates functionally and roughly 100 times higher than that of morphine and 30 times high- physiologically relevant channels.4 Nicotinic receptors are widely er than that of nicotine, has been attributed to its high affinity for distributed in the brain, where they primarily modulate the release the a4b2 subtype. Worth mentioning, (À)-2 and (+)-2 are charac- of other neurotransmitters and, to a lesser extent, mediate synaptic terized by similar affinities for nAChRs and almost identical ED50 transmission.5 Neuronal nAChRs, selectively activated by (S)-nico- values in the mouse tail-flick antinociception assay.13d,14,15 tine 1 (Fig. 1), are involved in various processes such as cognition, Among the synthetic epibatidine-related compounds, (±)-epib- learning and memory, cerebral blood flow and metabolism, as well oxidine 3 (Fig. 1), in which the 3-methylisoxazolyl moiety has re- as an array of pathological conditions such as Alzheimer’s and Par- placed the chloropyridinyl ring of the parent derivative, behaved kinson’s diseases, mild cognitive impairment (MCI), schizophrenia, as a potent a4b2 nicotinic receptor agonist, 10-fold less potent than epilepsy, Tourette’s syndrome, anxiety, depression, attention-defi- epibatidine as antinociceptive agent but about 20-fold less toxic.16 cit hyperactivity disorder (ADHD), and nicotine addiction.1,2,6,7 The presence of the 3-methylisoxazole ring was similarly effective The heteromeric a4b2 receptors, the most abundant subtype in in the structure of (S)-ABT-418 4 (Fig. 1), a nicotine-related a4b2 the mammalian CNS, and the homomeric a7 channels are privi- selective full agonist, which entered Phase I for the treatment of leged biological targets in the search for selective nAChR ligands cognitive dysfunction and was later on discontinued.2,7,17 A further with therapeutic potential.2,8 As far as the number of nicotinic ago- relevant example of structural analogue of epibatidine is the unsat- nists isolated from natural sources is taken into consideration,9 urated derivative (±)-UB-165 5, containing the 9-azabicy- clo[4.2.1]nonene skeleton, a high affinity nicotinic partial agonist * Corresponding author. Tel.: +39 02 50319327; fax: +39 02 50319326. which allowed to clarify the involvement of the a4b2 subtype in 18,19 E-mail address: [email protected] (C. Dallanoce). modulating dopamine release from rat striatal synaptosomes. 0960-894X/$ - see front matter Ó 2008 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2008.07.016 4652 L. Rizzi et al. / Bioorg. Med. Chem. Lett. 18 (2008) 4651–4654 H Cl H CH3 CH3 N N N N N N O O N N CH3 CH3 1 (S)-Nicotine 2 (−)-Epibatidine 3 (±)-Epiboxidine 4 (S)-ABT-418 H H Cl R CH3 N N N N N O O N CH3 5 (±)-UB-165 6 (±)-endo-Epiboxidine (±)-7: R=H (±)-8: R=CH3 Figure 1. Structures of model and target compounds in this study. In the present study, we aimed at further investigating epibox- Boc idine, that is, at a7 nAChRs, a subtype on which, to the best of our Br N knowledge, it was never assayed. To this end, we thought about a a Br flexible synthesis of (±)-3 allowing also the preparation of unsatu- + N rated structurally related derivatives. Accordingly, we describe a novel synthetic route to epiboxidine 3 (exo-isomer), its epimer Boc CO2Me CO2Me endo-epiboxidine 6, and the two unprecedented dehydro-ana- logues of epiboxidine 7 and 8. The target chiral compounds, whose 13 14 15 structures are reported in Figure 1, were prepared and tested as racemates. Boc As illustrated in the upper part of Scheme 1, the known prepa- N rations of 3 took advantage of the reaction of 7-azabicy- b-d O e,f 15 11 clo[2.2.1]heptane-2,7-dicarboxylic acid diesters 9a and 9b with the dianion of acetone oxime, followed by acidic treatment of intermediates 10a and 10b.16,20 As an alternative approach, we 16 planned to make use of a Stille palladium-catalyzed cross-coupling 21 reaction, which involved the coupling of enoltriflate 11 with 3- H methyl-5-tributylstannylisoxazole 12, as depicted in the lower Cl CH 3 g part of Scheme 1. + 12 N Initially, we made use of a known procedure to prepare 7-tert- HO butoxycarbonyl-7-azabicyclo[2.2.1]heptan-2-one 16, a key inter- SnBu3 22 mediate in one of the syntheses of (±)-epibatidine. The first step 17 18 of the sequence, a [4+2] cycloaddition of N-Boc-pyrrole 13, used in large excess, to methyl 3-bromopropiolate 14, was performed un- Scheme 2. (a) MW, 90 °C, 1.5 h, neat; (b)–(d) see Ref. 22; (e) (iPr)2NH/n-BuLi, der microwave heating (Scheme 2).23 These experimental condi- À78 °C; (f) N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonimide), À78 °C to rt; (g) NEt /THF, rt, 5 h. tions allowed reduction of the reaction time (from 30 to 1.5 h) 3 and improvement of the yield of the Diels-Alder adduct 15 (from 60% to 85%). Subsequently, we prepared the known trifluorometh- anesulfonate 1124 in 62% isolated yield by treatment of ketone 16 with LDA in THF at À78 °C25 followed by reaction with N-(5- chloro-2-pyridyl)bis(trifluoromethanesulfonimide)26 (Scheme 2). 3-Methyl-5-tributylstannylisoxazole 12 was obtained through the RO2C RO2C OH previously described 1,3-dipolar cycloaddition of tributylethynyl- O N N N 27 a b tin 17 to acetonitrile oxide. As a modification of the known pro- CO2Et 3 CH3 cedure, we chose to isolate the stable precursor of the 1,3-dipole, that is, the acetohydroximoyl chloride 18, which in turn was syn- 9a: R = Et 10a: R = Et thesized by reacting acetaldoxime with benzyltrimethylammoni- 9b: R = tert-Bu 10b: R = tert-Bu 28,29 um tetrachloroiodate (BTMA ICl4). In this way, the target (a) Acetone oxime, nBuLi; (b) conc. HCl, 80ºC. tributylstannylisoxazole 12 was prepared in acceptable yields (45–50%). Boc The Stille cross-coupling reaction of triflate 11 to isoxazole 12, CH3 N performed in the presence of the Tris(dibenzylideneacetone)dipal- OTf ladium(0)-chloroform adduct, triphenylphosphine, and anhydrous 3 + N Bu Sn 3 O ZnCl2, produced the 7-azabicyclo[2.2.1]hept-2-ene derivative 19 in 90% yield (Scheme 3).30 Removal of the N-Boc protection of 19 with 11 12 a 4 N solution of HCl in dioxane afforded the secondary amine 7, Scheme 1. (A) Key steps of the known synthetic strategy to epiboxidine 3. (B) which was converted into the corresponding N-methyl derivative Retrosynthesis of 3 based on a Stille coupling reaction. 8 by a standard reaction with formaldehyde followed by reduction L. Rizzi et al. / Bioorg. Med. Chem. Lett. 18 (2008) 4651–4654 4653 Boc CH3 N a N b,c d 11 O 78 19 Boc Boc CH3 N N e f N b 19 O 3 x HCl O N CH3 20 21 g g b 7 7 fumarate 8 8 fumarate 20 6 x HCl Scheme 3.